Our approach is centered on a personalized, multi-modal strategy that factors in your medical history and biochemical profile derived from comprehensive laboratory assessments. Your individualized care plan will feature specific nutraceuticals and, where necessary, bio-identical hormones. These interventions are designed to optimize your cellular health and reinvigorate the functionality of your genes.
To halt the progression of macular degeneration most effectively, it's crucial to initiate treatment as soon as possible, before macula damage becomes permanent. Once the damage is irreversible, our options are limited to stabilizing the condition. However, early intervention can potentially reverse vision loss.
Our approach includes a targeted mix of hormonal treatments, carefully chosen nutraceuticals, and personalized nutritional guidance derived from individual lab tests. We aim to reactivate genes that have become inactive as a result of aging. Our studies indicate that this method can not only stabilize but potentially enhance vision in nearly half of the participants suffering from macular degeneration. Additionally, it could decrease the frequency of eye injections and reduce the chances of the condition worsening from the dry type to the more severe wet type.
We highly advocate for patients to undertake this program, which is grounded in scientific research, as soon as possible. Early participation can significantly diminish the likelihood of the disease advancing to an irreversible stage.
Our approach is centered on a personalized, multi-modal strategy that factors in your medical history and biochemical profile derived from comprehensive laboratory assessments. Your individualized care plan will feature specific nutraceuticals and, where necessary, bio-identical hormones. These interventions are designed to optimize your cellular health and reinvigorate the functionality of your genes.
To halt the progression of macular degeneration most effectively, it's crucial to initiate treatment as soon as possible, before macula damage becomes permanent. Once the damage is irreversible, our options are limited to stabilizing the condition. However, early intervention can potentially reverse vision loss.
Difficulty seeing in dim light.
Slowly progressive blurred vision not improved with glasses.
Distorted Vision: Straight lines might appear wavy or curved, which is a sign of wet macular degeneration.
Spots: There may be dark blind spots in the center of vision which may be transitory.
Difficulty seeing in dim light..
Slowly progressive blurred vision not improved with glasses.
Distorted Vision: Straight lines might appear wavy or curved, which is a sign of wet macular degeneration.
Spots: There may be dark blind spots in the center of vision which may be transitory
The HOMING Method guides the personalized care plan for Age-related Macular Degeneration (AMD).
HOMING is an acronym for Hormones, Oxidation, Methylation, Inflammation, Nutrition and Genetics. The goal is to improve cell biochemistry either directly or by epigenetic mechanisms, (reawakening dormant genes that down regulate with aging)
Literature Citation demonstrating stability and improvement of dry and wet AMD
In 2020, we conducted a study with 365 dry or wet AMD patients. We found that stability or improvement was possible for dry or wet AMD.
48% of dry AMD improved.
60% of wet AMD improved.
In 2020, we conducted a study with 365 dry or wet AMD patients. We found that stability or improvement was possible for dry or wet AMD.
It won the Advancements in Health Care Award.
Had it not been for our success in many patients we may never have pursued macular degeneration.
We discuss the discovery process in our presentations.
The HOMING method has been a success in many clinical conditions indicating that addresses root causes of disease.
It won the Advancements in Health Care Award.
Had it not been for our success in many patients we may never have pursued macular degeneration.
We discuss the discovery process in our presentations.
Prevent AMD
Failures of Dark Adaptation Testing
Drusen
Dry AMD with Vision Loss
Reducing conversion of Dry to Wet AMD
Wet AMD
Diabetic Retinopathy
Vein Occlusions
Preparing for Cataract Surgery in Eyes with AMD
Glaucoma
Retinitis Pigmentosa
Macular hole
Artery Occlusion
Macular Pucker (Epiretinal Membrane)
Floaters
Retinal Detachment
Irreversible Advance Macular Degeneration
Prevent AMD
Failures of Dark Adaptation Testing
Drusen
Dry AMD with Vision Loss
Reducing conversion of Dry to Wet AMD
Wet AMD
Diabetic Retinopathy
Vein Occlusions
Preparing for Cataract Surgery in Eyes with AMD
Glaucoma
Retinitis Pigmentosa
Macular hole
Artery Occlusion
Macular Pucker (Epiretinal Membrane)
Floaters
Retinal Detachment
Irreversible Advance Macular Degeneration
Board Certified Ophthalmology
Ph.D. in Biochemistry
Board Certified Ophthalmologist / Biomedical Engineer
PhD in Biochemistry
In the quest for preserving vision and improving the quality of life for those affected by age-related macular degeneration (AMD), the innovative approach adopted by Dr. George W. Rozakis and Dr. Brian A. Bakke stands as a beacon of hope. Their work, deeply rooted in the principles of personalized care, highlights the significance of timely intervention in combating this leading cause of vision loss. The HOMING trial, a retrospective pilot study led by these pioneers, offers compelling evidence on the efficacy of a personalized bio-identical hormone dietary supplement and nutritional care plans for AMD patients.
Age-related macular degeneration, a condition characterized by the deterioration of the central portion of the retina, impacts millions worldwide, significantly affecting their ability to read, drive, and recognize faces. While the exact cause of AMD remains elusive, factors such as oxidative stress, inflammation, and genetic predispositions are known contributors. It is here, in the intricate dance of cellular biochemistry, that Dr. Rozakis and Dr. Bakke have directed their focus, aiming to not just halt but reverse the degenerative process.
The HOMING protocol, named after its components—Hormones, Oxidative stress, Methylation, Inflammation, and Gene expression—represents a holistic approach to AMD treatment. By assessing individual patient needs through detailed history and blood testing, the protocol personalizes treatment, incorporating bio-identical hormones, dietary supplements, and nutrition recommendations designed to target the underlying mechanisms of AMD.
Clinical Success and Patient Outcomes
The outcomes of the HOMING trial are nothing short of promising. With 365 AMD patients under observation, the study witnessed remarkable improvements in both dry and wet AMD cases. Specifically, 60% of wet AMD patients reported enhanced visual acuity or a reduction in anti-VEGF injection frequency, while 48% of dry AMD patients noted improved vision. These self-reported outcomes are supported by favorable responses in serum concentrations of CRP, HbA1c, and homocysteine, underscoring the potential of the HOMING protocol to positively influence AMD's pathophysiology.
The Timeliness of Intervention
One of the most critical insights from Dr. Rozakis and Dr. Bakke's work is the importance of early intervention. The findings suggest that initiating the HOMING protocol early in AMD's progression offers a greater chance for positive outcomes, highlighting the need for timely diagnosis and treatment. This approach aligns with the broader understanding in medicine that early and personalized care can significantly alter the course of chronic diseases.
A Call for Comprehensive Care
The HOMING trial underscores the necessity of a multidisciplinary approach to AMD management. The integration of optometry, ophthalmology, nutrition, and endocrinology into patient care plans emphasizes the complex nature of AMD and the multifaceted strategy required for its management. It's a call to action for healthcare providers to adopt a more holistic view of patient care, one that considers the interplay of various bodily systems and the benefits of targeting underlying disease mechanisms.
The Path Forward
The work of Dr. Rozakis and Dr. Bakke serves as a powerful testament to the potential of innovative, personalized treatment plans in managing age-related macular degeneration. Their pioneering efforts not only offer hope to those battling AMD but also pave the way for future research and clinical practices that prioritize personalized care. As we look to the future, it's clear that the pathways to improvement for AMD patients lie in timely, tailored interventions that address the unique needs of each individual. Through continued exploration and application of holistic treatment modalities, we can aspire to preserve vision and improve the lives of those affected by AMD.
Watch the Vision Revolution Masterclass here.
Our study followed patients for 6 months. Those who improved did so generally between 2 and 6 months. Unpublished data is showing that these effects are not lost out to 2-3 years and additional improvement is possible with more time. Time and compliance with the program are the keys to continued success.
Similar to exercise and dietary practices, the favorable changes in your blood chemistry can only be sustained as long as you are taking your program.
Yes. Consistently adhering to our program has led to marked improvements for our patients. It is the combination of time and unwavering commitment to the program that paves the way for enduring success.
This decision is made by you retina doctor. However it is reasonable to ask to decrease the time between injection if the OCT scans show no remaining fluid because the HOMING Method, according to scientific literature, may decrease the creation of growth factors in the eye (for which you are receiving the injections).
The Macular Program is a form of anti-aging medicine since macular degeneration is actually called AGE RELATED macular degeneration. Fighting aging is fighting AMD. What is nice is that treating AMD with HOMING also benefits other aging symptoms which is why we want to know about your eye AND General Health.
Age-Related Macular Degeneration (AMD), whether dry or wet, is a complex condition influenced by numerous factors. Our HOMING method helps to prevent, stabilize and even reverse macular degeneration.
Geographic Atrophy is a special form of dry macular degeneration that is felt to be caused by inflammation. The HOMING method reduces inflammation. Our clinical suspicion is that GA does not worsen if a patient is on the HOMING Method. This is an important matter because new drugs now exist to fight inflammation in eyes with GA, but these drugs need to be injected into the eye. We hope the HOMING method will allow patients to avoid eye injections for GA. The smart move is to be on the HOMING method and have the GA closely followed for progression. If no progression, then you don’t need shots. It’s your call.
MacularProgram© 2023 | All Rights Reserved
All Rights Reserved 2024
Macular Program
Contact Us:
440-777-2667
Email Us: info@macularprogram.com